positive
Eli Lilly’s Mounjaro Becomes India’s 2nd Highest Selling Drug in September 2025
Eli Lilly’s weight-loss drug Mounjaro rose to become India’s second highest-selling pharmaceutical in September 2025, with sales up 42% month-on-month. The surge reflects rising obesity prevalence and growing clinical adoption of modern diabetes and weight management therapies. Strengthened distribution networks and physician endorsements accelerated uptake, positioning Mounjaro as a key player in India’s expanding metabolic health segment and underscoring demand for innovative, long-term treatment solutions in chronic lifestyle care.
Companies:
- Bank First Corporation
Tags:
- Bank First Corporation
- growth stocks
Indiatoday• By struti
Explore:Mutual Fund AI Screening
positive
Eli Lilly’s Mounjaro Becomes India’s 2nd Highest Selling Drug in September 2025
Eli Lilly’s weight-loss drug Mounjaro rose to become India’s second highest-selling pharmaceutical in September 2025, with sales up 42% month-on-month. The surge reflects rising obesity prevalence and growing clinical adoption of modern diabetes and weight management therapies. Strengthened distribution networks and physician endorsements accelerated uptake, positioning Mounjaro as a key player in India’s expanding metabolic health segment and underscoring demand for innovative, long-term treatment solutions in chronic lifestyle care.
Companies:
- Bank First Corporation
Tags:
- Bank First Corporation
- growth stocks
Indiatoday• By struti
Explore:Mutual Fund AI Screening
1 min read
69 words
Mounjaro’s 42% month-on-month sales growth propels it to the position of India’s second top-selling drug in September 2025, highlighting a strong market shift towards innovative obesity management treatments.
Eli Lilly’s weight-loss drug Mounjaro rose to become India’s second highest-selling pharmaceutical in September 2025, with sales up 42% month-on-month. The surge reflects rising obesity prevalence and growing clinical adoption of modern diabetes and weight management therapies. Strengthened distribution networks and physician endorsements accelerated uptake, positioning Mounjaro as a key player in India’s expanding metabolic health segment and underscoring demand for innovative, long-term treatment solutions in chronic lifestyle care.
Eli Lilly’s weight-loss drug Mounjaro rose to become India’s second highest-selling pharmaceutical in September 2025, with sales up 42% month-on-month. The surge reflects rising obesity prevalence and growing clinical adoption of modern diabetes and weight management therapies. Strengthened distribution networks and physician endorsements accelerated uptake, positioning Mounjaro as a key player in India’s expanding metabolic health segment and underscoring demand for innovative, long-term treatment solutions in chronic lifestyle care.
Companies:
- Bank First Corporation
Tags:
- Bank First Corporation
- growth stocks
- Bank First Corporation
- growth stocks
- insider ownership
- regional banking
- earnings growth